Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463983 | 1.00 | HRH3 (0.59) | HRH3SLC6A2SLC6A4SLC6A3HCAR2 | |
| SCHEMBL29274950 | 1.00 | HRH3 (0.59) | HRH3SLC6A2SLC6A4SLC6A3HCAR2 | |
| SCHEMBL10956783 | 0.85 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL440476 | 0.85 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL414249 | 0.85 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL23273783 | 0.85 | SLC6A2 (0.46) | HRH3SLC6A2SLC6A4SLC6A3HCAR2 | |
| SCHEMBL1818681 | 0.85 | SLC6A2 (0.46) | HRH3SLC6A2SLC6A4SLC6A3HCAR2 | |
| SCHEMBL1815990 | 0.85 | SLC6A2 (0.46) | HRH3SLC6A2SLC6A4SLC6A3HCAR2 | |
| SCHEMBL1816991 | 0.85 | SLC6A2 (0.46) | HRH3SLC6A2SLC6A4SLC6A3ARG1 | |
| SCHEMBL1817287 | 0.85 | SLC6A2 (0.46) | HRH3SLC6A2SLC6A4SLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |
| WO-2009006473-A2 | PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | HRH3 4501/4885SLC6A2 4581/4885SLC6A4 4650/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | HRH3 4506/4885SLC6A2 4281/4885SLC6A4 4306/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | HRH3 4490/4885SLC6A2 4600/4885SLC6A4 4665/4885 |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | HRH3 4506/4885SLC6A2 4281/4885SLC6A4 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.